Not finding it? Sign in to also search OpenAlex live.
-
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.2023 Journal of Clinical Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
Kristoffer Staal Rohrberg, Mariana Brandão, Eduardo Castañón Álvarez, Enriqueta Felip, Eelke Hiddo Gort, T. Jeroen N. Hiltermann, +14 more
22citations -
Gammaherpesvirus infection impairs lung fibrosis resolution through PD-L1+ fibroblasts and PD-1+ CD8+ T cell interaction2026 Mucosal Immunology article Medicine Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Open access
Laura Kempen, Domien Vanneste, Justine Javaux, Lorène Dams, R Sandor, M. Pathammavong, +14 more
0citations -
A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer
Hanieh Abedian Kalkhoran, J. Zwaveling, Bert N. Storm, Sylvia A. van Laar, Johanneke E.A. Portielje, Henk Codrington, +4 more
14citations -
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors2020 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 1 patent
Aung Naing, Justin F. Gainor, Hans A. J. Gelderblom, Patrick M. Forde, Marcus Otho Butler, Chia‐Chi Lin, +11 more
86citations -
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors2021 Clinical Cancer Research article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 7 patents
Giuseppe Curigliano, Hans A. J. Gelderblom, Nicolas Mach, Toshihiko Doi, David Wai-Meng Tai, Patrick M. Forde, +13 more
359citations -
Data from Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans A. J. Gelderblom, Nicolas Mach, Toshihiko Doi, David Wai-Meng Tai, Patrick M. Forde, +13 more
0citations -
Data from Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans A. J. Gelderblom, Nicolas Mach, Toshihiko Doi, David Wai-Meng Tai, Patrick M. Forde, +13 more
0citations -
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy2021 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 3 patents
Kim E. Kortekaas, Saskia J A M Santegoets, Liselotte Tas, Ilina Ehsan, Pornpimol Charoentong, Helena C. van Doorn, +3 more
28citations -
Intensity- and time-matched acute interval and continuous endurance exercise similarly induce an anti-inflammatory environment in recreationally active runners: focus on PD-1 expression in Tregs and the IL-6/IL-10 axis2023 European Journal of Applied Physiology article Medicine Exercise and Physiological Responses Open access
Sebastian Proschinger, Alexander Schenk, Inga Weßels, Lars Donath, Ludwig Rappelt, Alan J. Metcalfe, +1 more
13citations -
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes2020 Cancer Cell article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 3 patents
Floris F. Dammeijer, Mandy van Gulijk, Evalyn E.A.P. Mulder, Melanie M. Lukkes, Larissa Klaase, Thierry P. P. van den Bosch, +18 more
720citations -
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment2023 Nature Communications article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 2 patents
Markus Haake, Beatrice Haack, Tina Schäfer, Patrick N. Harter, Greta Mattavelli, Patrick Eiring, +47 more
108citations -
PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer2020 Critical Reviews in Oncology/Hematology article Medicine Endometrial and Cervical Cancer Treatments Open access cited by 1 patent
Cathalijne Post, Anneke M. Westermann, Tjalling Bosse, Carien L. Creutzberg, Judith R. Kroep
61citations -
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Georgina Venetia Long, Nitya Nair, Daniel Marbach, Richard A. Scolyer, Sabine Wilson, Denise Cotting, +19 more
23citations -
PD-1 Overexpression in Sézary Syndrome Is Epigenetically Regulated2023 Journal of Investigative Dermatology article Medicine Cutaneous lymphoproliferative disorders research Open access
Safa Najidh, Willem H. Zoutman, Anne M.R. Schrader, Rein Willemze, Cornelis P. Tensen, Maarten H. Vermeer
1citations